Other serum biomarkers have been proposed for ovarian cancer detection, namely human epididymis protein 4 (HE4), alone or in combination with CA125, but the available data are insufficient to conclude a significant improvement in the clinical performance of the assays versus the CA125 assay alone [116]. The gene discussed is MUC16; the disease is ovarian carcinoma.